FSHD UK
FSHD News
Clinical Trial & Studies Updates
-
Avidity Announces data from phase 1/2 FORTITUDE™ trial
Read more: Avidity Announces data from phase 1/2 FORTITUDE™ trialAvidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
-
Fulcrum Therapeutics and Sanofi collaborate to commercialize Losmapimo
Read more: Fulcrum Therapeutics and Sanofi collaborate to commercialize LosmapimoFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
Research News shared by our teams
-
SAT-3247 improves muscle function in FSHD mouse model
Read more: SAT-3247 improves muscle function in FSHD mouse modelRuth Hereford shared this information on a research funded by Canada (also a member of Project Mercury)
-
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
Read more: Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular DystrophyNeil Camarta (FSHD Canada) shared this research with us on muscle regeneration
-
Sibling study reveals mechanism for genetic disease
Read more: Sibling study reveals mechanism for genetic diseaseYusuke Nishimura who is part of the Research team has recently had a paper published
Special Events
-
Rare Disease Day
Read more: Rare Disease DayAt the kind invitation of Dr. Alberto Malerba, Lecturer in Gene Therapy at the Royal Holloway, University of London, Rajeshri Badiani presented the FSHD UK journey
-
FSHD UK at the Avidity FORTITUDE Investigator Meeting
Read more: FSHD UK at the Avidity FORTITUDE Investigator MeetingIn October 2023 Rajeshri (aka ‘Raj’ ) Badiani was interviewed by Kristi Clark, VP – Clinical Operations, Avidity Biosciences on Raj’s FSHD journey and her work on FSHD UK especially in progressing clinical trials in the UK.